A recent article in the Journal of the American Medical Association-Oncology (JAMA) contains an exciting strategy (made possible again by all the work of the Human Genome Project) for treatment decision making and finding recurrences earlier for those diagnosed with colorectal cancer. Colorectal cancer is the third most common cancer. Treatment involves...
Read More
In a nutshell This study investigated the effectiveness of stereotactic body radiotherapy (SBRT) in metastatic (spread to other parts of the body) colorectal cancer. Researchers suggested that SBRT is associated with improved tumor response and manageable side effects. Some background Colorectal cancer is the second most commonly diagnosed cancer in...
Read More
In a nutshell This study investigated the effects of World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) guidelines in the health-related quality of life of patients who survived colorectal cancer. Researchers suggested that following these guidelines might be associated with improved health. Some background In 2007 the...
Read More
In a nutshell This study investigated the short- and long-term outcomes of totally robotic and robotic-assisted colon surgery in the treatment of colon cancer. Researchers suggested that totally robotic surgery is a safe and effective treatment option for these patients. Some background Robotic methods (use of robotic arms) are now widely used in...
Read More
In a nutshell This trial is examining the effectiveness and safety of a combined treatment with pembrolizumab (Keytruda) and binimetinib (Mektovi). The main outcome to be measured is the tumor response to the treatment. This trial is recruiting in the United States and Canada. The details Colorectal cancer is the third most common cancer in the...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with colorectal cancer or other solid tumors. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of...
Read More
New: Thanks to InVideo, we have a video version of the post below. Check it out at bottom of the post. Incredible immunotherapy responses in some cancers, but not in others, have puzzled the research community. What is it about some cancers that allows the immune system to be activated? Why are some cancers able to evade the immune system even when...
Read MoreIn a nutshell This study compared the survival outcomes of patients with rectal cancer who underwent short- or long-course radiation therapy (RT). Researchers suggested that long-course RT was associated with greater tumor response and survival. Some background Colorectal cancer is the third most common cancer diagnosed in the United States. The...
Read More
In a nutshell This study investigated the short- and long-term occurrence of hormonal and metabolic disorders in colorectal cancer survivors. Researchers suggested that the occurrence of these types of disorders was higher in these patients. Some background Colorectal cancer is the third most common cancer in the United States. With current...
Read More
In a nutshell This trial is examining the effectiveness and toxicity of PolyPEPI1018 vaccine in the treatment of advanced colorectal cancer. The main outcome to be measured is tumor response to the treatment. This trial will be conducted in Italy, and Minnesota, US. The details The standard treatment for metastatic (spread to other parts of the body)...
Read More
In a nutshell This trial is examining the effectiveness and safety of treatment with nivolumab (Opdivo) and relatlimab in patients with advanced colorectal cancer. The main outcome to be measured will be tumor response to the treatment. This trial is being conducted in Maryland, US. The details Colorectal cancer is the third most common cancer in the...
Read More
In a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...
Read More
